Cerebrospinal fluid biomarker candidates for parkinsonian disorders.

Cerebrospinal fluid biomarker candidates for parkinsonian disorders.
复制标题

DOI:
10.3389/fneur.2012.00187
复制
发表时间:
2012
影响因子:
3.4
通讯作者:
Mondello S
Mondello S
中科院分区:
医学3区
文献类型:
--
作者:
Constantinescu R;Mondello S

文献摘要

参考文献

被引文献

相似文献

帕金森病是一大类神经退行性疾病,包括特发性帕金森病(PD)和非典型帕金森病(APD),如多系统萎缩、进行性核上性麻痹、皮质基底变性和路易体痴呆。这些疾病的病因尚不清楚,虽然它被认为是遗传和环境因素的结合。开发有效的疾病改善治疗策略的最大障碍之一是缺乏生物标志物。需要可靠的生物标志物来进行早期和准确的诊断,测量疾病进展和对治疗的反应。在这篇综述中讨论了几种最有前途的脑脊液生物标志物候选物。α -突触核蛋白似乎与突触核蛋白病的发病机制密切相关,其水平可在脑脊液和血浆中测定。以类似的方式,tau蛋白的积累似乎参与了tau病的发病机制。尿酸盐,一种有效的抗氧化剂,似乎与患帕金森病的风险及其进展有关。与PD和健康对照相比,APD患者的神经丝轻链水平升高。新的“组学”技术是强有力的工具,为这些疾病的病理病因学提供了新的见解。讨论了开发生物标志物时遇到的一些困难,并对未来进行了展望。
The Parkinsonian disorders are a large group of neurodegenerative diseases including idiopathic Parkinson’s disease (PD) and atypical Parkinsonian disorders (APD), such as multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, and dementia with Lewy bodies. The etiology of these disorders is not known although it is considered to be a combination of genetic and environmental factors. One of the greatest obstacles for developing efficacious disease-modifying treatment strategies is the lack of biomarkers. Reliable biomarkers are needed for early and accurate diagnosis, to measure disease progression, and response to therapy. In this review several of the most promising cerebrospinal biomarker candidates are discussed. Alpha-synuclein seems to be intimately involved in the pathogenesis of synucleinopathies and its levels can be measured in the cerebrospinal fluid and in plasma. In a similar way, tau protein accumulation seems to be involved in the pathogenesis of tauopathies. Urate, a potent antioxidant, seems to be associated to the risk of developing PD and with its progression. Neurofilament light chain levels are increased in APD compared with PD and healthy controls. The new “omics” techniques are potent tools offering new insights in the patho-etiology of these disorders. Some of the difficulties encountered in developing biomarkers are discussed together with future perspectives.
DOI: 10.1136/jnnp.2009.199950
发表时间: 2010-10-01
影响因子: 11
作者:
Alves, Guido;Bronnick, Kolbjorn;Mulugeta, Ezra
通讯作者: Mulugeta, Ezra
DOI: 10.1093/brain/awm304
发表时间: 2008-02-01
期刊: BRAIN
影响因子: 14.5
作者:
Bogdanov, Mikhail;Matson, Wayne R.;Beal, M. Flint
通讯作者: Beal, M. Flint
DOI: 10.1212/wnl.57.3.456
发表时间: 2001-08-14
期刊: NEUROLOGY
影响因子: 9.9
作者:
Abbott, RD;Petrovitch, H;Ross, GW
通讯作者: Ross, GW
DOI: 10.1016/j.expneurol.2003.08.008
发表时间: 2003-11-01
影响因子: 5.3
作者:
Brooks, DJ;Frey, KA;Stoessl, AJ
通讯作者: Stoessl, AJ
DOI: 10.1016/j.parkreldis.2008.05.001
发表时间: 2009-03-01
影响因子: 4.1
作者:
Constantinescu, Radu;Zetterberg, Henrik;Rosengren, Lars
通讯作者: Rosengren, Lars